Facilities Inspection. Purchaser shall have the right, for and during the period ending 45 calendar days following the date of execution of this Agreement (the “Inspection Period”), to inspect the physical condition of the Real Property for use as a bank, including, without limitation, compliance of the Real Property with the provisions of the Americans with Disabilities Act (collectively, “Inspection Issues”). These inspections shall be conducted during regular business hours by qualified inspectors or employees of Purchaser or its affiliates following not less than three business days notice to Seller. Prior to entry upon the property, Purchaser will confirm to Seller the existence of general liability insurance in coverage amounts reasonably acceptable to Seller. Any physical disturbance to the Real Property shall be subject to Seller’s prior approval, which may be subject to such reasonable repair and restoration conditions as Seller may impose (including, without limitation, the obligation to repair any disturbed area to its condition immediately prior to that disturbance). Purchaser promptly shall provide Seller with copies of any and all written reports in connection with those inspections, at no cost to Seller, upon Seller’s request.
Facilities Inspection. (i) Purchaser shall have the right, at Purchaser’s expense, for and during the period ending 45 calendar days following the date of execution of this Agreement (the “Inspection Period”), to inspect the physical condition of the Owned Real Property for use as a bank, including, without limitation, compliance of the Owned Real Property with the provisions of the Americans with Disabilities Act (collectively, “Inspection Issues”). These inspections shall be conducted during regular business hours by qualified inspectors or employees of Purchaser or its affiliates following not less than three business days notice to Seller. Prior to entry upon the property, Purchaser will confirm to Seller the existence of general liability insurance in coverage amounts reasonably acceptable to Seller. Any physical disturbance to the Owned Real Property shall be subject to Seller’s prior approval, which may be subject to such reasonable repair and restoration conditions as Seller may impose (including, without limitation, the obligation to repair any disturbed area to its condition immediately prior to that disturbance). Purchaser promptly shall provide Seller with copies of any and all written reports in connection with those inspections, at no cost to Seller, upon Seller’s request.
(ii) Purchaser shall return the Owned Real Property to the condition existing prior to any tests and inspections performed by Purchaser or Purchaser’s representatives, as determined by Seller in its reasonable discretion. Purchaser shall indemnify and hold Seller harmless from and against any and all damages, mechanics’ liens, liabilities, losses, demands, actions, causes of action, claims, costs and expenses (including, without limitation, reasonable attorneys’ fees and the cost of appeals) from or relating to Purchaser’s or its employee’s, agent’s, representative’s, or contractor’s entry onto the Owned Real Property, and any inspections or other matters performed by Purchaser with respect to the Owned Real Property, whether prior to, during, or after the Inspection Period. The provisions of this Section 1.10(c)(ii) shall survive Closing or any termination of this Agreement.
Facilities Inspection. During the Term of this Agreement, NeoPharm shall have the right, at its expense, to audit the Facility for Akorn's compliance with GMPs and any other applicable laws. NeoPharm agrees to provide Akorn with reasonable prior notice of the date of such audit. In addition to the foregoing, NeoPharm shall have the right to designate an individual to be at the Facility to monitor each Processing Run. NeoPharm agrees that its employees or agents who inspect the Facility or who are on site at the Facility during a Processing Run will comply with Akorn's rules, regulations and GMPs.
Facilities Inspection. Representatives of either Party may upon reasonable notice, and at times reasonably acceptable to the other Party, visit any facilities where any pre-clinical or clinical tests or Clinical Trials are being carried out in respect of the Crohn’s EIR Product or Licensed Products and any facilities where the Compound or the Crohn’s EIR Product or Licensed Products licensed by the inspecting Party to the other Party hereunder are being Manufactured under license from the inspecting Party hereunder and shall be entitled to consult informally during any such visit or by telephone or facsimile communication with personnel at any such facilities. The rights granted to a Party under this Section 9.4 are supplemental to and do not limit or modify the inspection rights granted to such Party (or its Affiliates) in the Supply Agreements, the Trademark License Agreement (Alfa to Salix) or the Trademark License Agreement (Salix to Alfa), as appropriate.
Facilities Inspection. Following execution of this Agreement and through the Closing Date, ENTEK, at its sole risk and expense, shall complete any and all inspections and its "As Is" approval of all equipment and facilities attributable to or owned or used in connection with the Properties, to confirm for itself that the Properties are in reasonable operating condition consistent with oil and gas industry standards.
Facilities Inspection. In order to maintain good communication, UCB agrees that AMYLIN shall, upon reasonable notice, be permitted to have a reasonable number of representatives of its technical staff present at UCB’s plant at all reasonable times during working hours, to monitor and participate in the manufacture of Product pursuant to this Agreement. UCB shall, at all times as may be reasonable, allow AMYLIN representatives to visit and inspect its manufacturing facilities where Product is being manufactured and to consult with UCB personnel to discuss and review the status of the work being done by UCB under this Agreement, and to perform, at AMYLIN’s expense, quality assurance audits. Management of such AMYLIN representatives, including their compensation, will be the responsibility of AMYLIN. AMYLIN shall ensure that its representatives comply with the UCB safety and access regulations applicable in UCB’s manufacturing facilities, that have been provided in writing to AMYLIN prior to each visit.
Facilities Inspection. UCB shall permit Regulatory Authorities access to those areas of the manufacturing facilities where Product is manufactured, stored or handled, and to manufacturing records of Product manufactured by UCB so that such Regulatory Authorities may perform an inspection and audit of its facilities and activities (during reasonable business hours and after reasonable notice).
Facilities Inspection. SCE shall be allowed access to Implementer’s and Subcontractors’ facilities to inspect, observe tests, expedite manufacture, and obtain data for the Material and Documentation.
Facilities Inspection. During the term of this Agreement, Xxxxx & Nephew may, upon at least fifteen (15) days prior written notice to ArthroCare and during ArthroCare’s regular business hours, inspect and audit the facilities being used by ArthroCare for production of the ArthroCare Manufactured Products being purchased by Xxxxx & Nephew from ArthroCare under this Agreement solely for the purpose of assuring material compliance by ArthroCare with prevailing FDA or relevant Regulatory Agency good manufacturing practices and ISO 13485; 2003 requirements; provided, however, such inspections and audits shall not be conducted more than once per year. Each Xxxxx & Nephew representative or agent conducting such inspection or audit shall be bound to hold all information in confidence except as necessary to communicate to Xxxxx & Nephew ArthroCare’s material non-compliance with prevailing FDA or relevant Regulatory Agency good manufacturing practices or ISO 13485; 2003 requirements. Each inspection or audit shall be conducted in a manner so as to minimize disruption of the business operations of ArthroCare. If such an inspection or audit reveals that such ArthroCare facilities do not materially comply with prevailing FDA or relevant Regulatory Agency good manufacturing practices or ISO 13485; 2003 requirements, then Xxxxx & Nephew shall promptly provide to ArthroCare written notice of such fact, which notice shall contain in reasonable detail the material deficiencies found in ArthroCare’s manufacturing facilities and, if practicable, those steps Xxxxx & Nephew reasonably and in good faith believes ArthroCare should undertake in order to remedy such deficiencies. ArthroCare shall use commercially reasonable efforts to remedy such deficiencies in a prompt manner after receipt of Xxxxx & Nephew’s notification thereof, and Xxxxx & Nephew shall have the right to re-inspect ArthroCare’s facilities in accordance with this Section 5.5 to confirm that all such deficiencies have been remedied. To the extent that Xxxxx & Nephew deems appropriate for prompt resolution of any issues under this Section 5.5, ArthroCare shall have direct access, under Xxxxx & Nephew’s control, to Xxxxx & Nephew’s Notified Body and FDA representative for resolution of issues regarding inspections and ArthroCare’s reasonable time and material expenses for this shall be reimbursed by Xxxxx & Nephew.
Facilities Inspection. The Contractor agrees to permit access to its facilities, subcontractor facilities and the
